TARCEVA: A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Exclusion Criteria1

• Adenocarcinoma of unknown origin.2.Prior or concurrent treatment with any other investigational agent3.Prior therapy targeting the epidermal growth factor receptor (EGFR)4.Prior allergic reaction to any compound chemically related to the study drug5.Previous (within the last 5 years) or concurrent malignancies6.Known history of brain metastases and/or leptomeningeal disease.7.Gastrointestinal tract disease resulting in an inability to take oral medication or requiring parenteral nutrition or affecting absorption. Active peptic ulcer disease.8.Uncontrolled bowel inflammatory disease (e.g., Crohn´s disease or ulcerative colitis).9.Myocardial infarction within the past 6 months.10.Second- or third-degree heart blocks unless pacemaker implanted.11.Significant dermatological disease.12.Inflammatory changes of the surface of the eye.13.Other significant medical condition, neurological or psychiatric disorder.14.Pregnant or lactating women (or potentially fertile women not using adequate contraception).15.Prior radiotherapy.16.Any condition potentially hampering compliance with the study protocol and follow-up schedule.